Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Item

http://www.wikidata.org/entity/Q30415832

Q30415832

about

Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.Variation in the Use of Chemoradiotherapy for Stage II and III Anal Cancer: Analysis of the National Cancer Data Base.Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.Concurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer-acute toxicity and treatment outcome Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity.Technical aspects of radiation therapy for anal cancer.Anal cancer treatment: current status and future perspectives.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review.Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.The differential diagnosis and interdisciplinary treatment of anal carcinoma Does endoscopic ultrasound improve detection of locally recurrent anal squamous-cell cancer?Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center.Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base.Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).Genital invasion or perigenital spread may pose a risk of marginal misses for Intensity Modulated Radiotherapy (IMRT) in anal cancer Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience.Sphincter preservation in anal cancer: a brief review.Radiation quality, like art, consists in drawing the line somewhere.Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis ACR Appropriateness Criteria®-Anal Cancer.Anal cancer: are we making progress?Optimal management of squamous cell carcinoma of the anal canal: where are we now?Optimal treatment strategies for anal cancer.Cancers of the anal canal: diagnosis, treatment and future strategies.Shifting paradigm in the management of anal canal carcinoma.Anal cancer: current standards in care and recent changes in practice.Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529 The prevalence and fate of the defunctioning stoma in patients with anal cancer; a regional experience following the ACT II trial.Investigational drugs for treating anal cancer and future perspectives.

P2860

Q28390359-165994F0-F8B3-4151-9005-5C68396C9F26 Q30409533-E51CEBC4-79A4-4870-9542-183DE84C004C Q31116556-C205C836-D04E-4BFE-8263-E023D0C73E5B Q33422634-EE0C7715-AD42-4184-A79F-BFA11399CD00 Q33429717-A9D63BCA-2F74-4D5E-B977-768A2F3D94B9 Q33431168-01DF4EDF-34BF-40DA-914F-6AE939D4C68D Q33593181-02FEE4BE-5147-4323-ACAF-A2D9ABBAD988 Q33646367-DAE703DD-1A5B-4255-B348-7DAE88B2D4F7 Q33729819-682ADDDA-A9CE-4E39-A4A4-2DAC73A2D382 Q33763918-32FE6EDA-FA6F-4714-8C25-05369FA26D56 Q33820797-D44B897D-B429-4520-9C77-A42ABC8F4A33 Q34465769-76E9DFE0-AAA6-440B-80EF-23DD1F261768 Q34584811-E7A72C13-B454-4986-8EFF-BFD8FC222561 Q34957320-026B7633-839E-4A7D-8A0B-386ECC06401D Q35086388-2DA207BF-05C6-4BC7-87CC-CAAAF5985D0A Q35113390-9DC05607-BA9A-45A0-864B-3922B3061A03 Q35530203-D1FDDBD4-D3C9-4172-AE44-2C0DD173E726 Q35548994-9C7B1B16-7E6D-4D0C-98FA-B70F8D06132B Q35565609-4E47E205-B306-425A-B8C0-B2D666ECBBCF Q35678065-A56DFE6D-779D-4CE1-B29A-1E44B60CA602 Q36009950-DAFFCCC8-1CE1-4974-8F4B-0B046FC7A454 Q36062623-7807E92B-600D-45E4-805B-6EED34B9002F Q36105656-026E051A-20EF-4C05-8767-7BED641E8098 Q36115829-9D3FB842-6DC6-4D18-BDAF-450539071716 Q36244369-CF3BD54A-4C31-4B2E-87EE-66D0C98FE40D Q36765574-C06DBD02-8D4F-480C-8A16-30B935B26FFA Q36786775-234A979D-5AEE-4E8E-9A61-37C625D98C0D Q37005884-58EDCE8D-9DB8-4547-9666-524B855C6375 Q37019668-A9848048-C68E-4FB9-81AA-F244E83F9268 Q37573426-DC2FC47D-2151-4D3B-BCE2-2C3AB882E1BE Q37584860-EE502FFF-1340-4091-A5C2-5C073A833D03 Q38078283-12EA4809-1B69-4194-85E0-7436DD42D912 Q38225033-D098278C-96F1-443D-AFD3-FC1B413196D1 Q38227802-38867A89-813C-4C1E-A94B-427363CC0551 Q38232853-E46368B3-CD6B-4055-B469-93EC9675899F Q38272464-FFE3766A-FCEF-4322-A319-C918AAB5E794 Q38315952-7E83F812-0822-44F8-B212-5C1D899AA707 Q38399664-E2ED55BC-BBB9-4692-8AFC-98D116BA5872 Q38611790-03E83460-F981-4D16-965B-9BFFC62DA501 Q38631415-4192BE6B-4BAC-4613-B501-3846A1DFE5B3

P2860

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Item

http://www.wikidata.org/entity/Q30415832

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu